COVID-19 Clinical Trial
Official title:
Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIR® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19
Verified date | January 2022 |
Source | Promomed, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.
Status | Completed |
Enrollment | 217 |
Est. completion date | December 30, 2021 |
Est. primary completion date | December 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Availability of the Informed Consent Form of the Patient Information Leaflet (PIL) signed and dated by patient. 2. Men and women aged 18 to 80 years inclusive at the time of signing the Informed Consent Form in PIL. 3. Confirmed case of COVID-19 at the time of screening based on SARS-CoV-2 RNA test using nucleic acid amplification (NAA) method. It is acceptable to include a patient with a presumptive COVID-19 diagnosis prior to receiving the results of SARS-CoV-2 RNA test made at the screening stage. 4. Hospital admission due to COVID-19. 5. Moderate severity infection with SARS-CoV-2: - Clinical signs: - Mandatory: CT pattern typical of a viral lesion (lesion volume is minimal or moderate; CT 1-2). - Additional (at least 1 of the following criteria): - body temperature > 38 °C; - RR > 22/min; - shortness of breath on exertion; - SpO2 < 95%; - Serum CRP > 10 mg/L. 6. Patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. Reliable means of contraception are: sexual abstinence, use of condom in combination with spermicide. For men (optional): Consent to avoid sexual contact with pregnant women for the duration of the study and for 3 months after its completion. Women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as men with infertility or a history of vasectomy. Exclusion Criteria: 1. Hypersensitivity to favipiravir, remdesivir and/or other components of the study drug. 2. Impossibility of CT procedure (for example, gypsum dressing or metal structures in the field of imaging). 3. History of vaccination against COVID-19. 4. History of presumptive or confirmed COVID-19 case of moderate, severe and extremely severe course of the disease. 5. Use of favipiravir or remdesivir within 10 days prior to screening. 6. The need to use drugs from the list of prohibited therapy. 7. Meeting the criteria for severe and extremely severe course of the disease. 8. Need for treatment in the intensive care unit. 9. Impaired liver function (AST and/or ALT = 2 UNL and/or total bilirubin = 1.5 UNL) at the time of screening. 10. Renal impairment (GFR < 60 ml/min) at the time of screening. 11. History of gout. 12. Positive testing for HIV, syphilis, hepatitis B and/or C. 13. Chronic heart failure FC III-IV according to New York Heart Association (NYHA) functional classification (see Appendix 2). 14. Malignancies in the past medical history. 15. Alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening. 16. Schizophrenia, schizoaffective disorder, bipolar disorder, or other history of mental pathology or suspicion of their presence at the time of screening. 17. Severe, decompensated or unstable somatic diseases (any disease or condition that threaten the patient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study). 18. Any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study. 19. Patient's unwillingness or inability to comply with procedures of the Study Protocol (in the opinion of physician investigator). 20. Pregnant or nursing women or women planning pregnancy. 21. Participation in another clinical study for 3 months prior to inclusion in the study. 22. Other conditions that, according to the physician investigator, prevent the patient from being included in the study. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Regional budgetary health care institution "Ivanovo Clinical Hospital named after Kuvaevs" | Ivanovo | |
Russian Federation | State Budgetary Institution of Healthcare of the City of Moscow "City Clinical Hospital No. 24 of the Department of Healthcare of the City of Moscow" | Moscow | |
Russian Federation | State Clinical Hospital ?50 | Moscow | |
Russian Federation | Regional Clinic Hospital of Ryazan | Ryazan' | |
Russian Federation | Medical institute Ogarev Mordovia State university | Saransk | |
Russian Federation | Smolensk clinical hospital ?1 | Smolensk |
Lead Sponsor | Collaborator |
---|---|
Promomed, LLC | Solyur Pharmaceuticals Group |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Clinical Status Improvement | Rate of clinical status improvement by WHO categorical ordinal scale of clinical status improvement by 2 or more categories by Day 10. WHO Ordinal Scale for Clinical Improvement (WHO-OSCI), 0 - uninfected (There are no clinical and virological signs of infection), 8 - dead, higher scores mean a worse outcome | By Visit 3, approximately 10 days | |
Primary | Time to Clinical Improvement | Time (in days) to improvement in clinical status by WHO categorical ordinal scale of clinical status improvement | 28 days | |
Secondary | Rate of Clinical Status Improvement | Rate of clinical status improvement by WHO categorical ordinal scale of clinical status improvement by 2 or more categories at Visits 2 (Day 5) and 4 (Day 14) | 14 days | |
Secondary | Rate of Clinical Status Improvement | Percentage of patients with clinical status of 0 and 1 point according to the WHO categorical ordinal scale of clinical improvement on Days 5, 10 and 14. | 14 Days | |
Secondary | End of Fever on Days of study | Percentage of patients with fever disappearance (body temperature < 37,2 °C in 3 consecutive measurements without antipyretic medication) an Days 5, 10 and 14. | 14 Days | |
Secondary | Change in the Level of Lung Damage According to CT | Assessment of lung injury (degree of damage by "empirical" visual scale and % of patients) according to CT data comparing to baseline. The number of patients in whom by the end of therapy there was an improvement in the condition of the lungs (a decrease in the volume of the lesion according to CT) | 14 Days | |
Secondary | Rate of Viral Elimination | Percentage of patients with SARS-CoV-2 elimination (negative test for SARS-CoV-2 by NAA method) on Days 5, 10, and 14. | 14 days | |
Secondary | Rate of Transfer to the Intensive Care Unit | Percentage of patients transferred to intensive care unit | 28 days | |
Secondary | Rate of the Use of Non-invasive Lung Ventilation | Percentage of cases with non-invasive lung ventilation | 28 Days | |
Secondary | Rate of the Use of Mechanical Ventilation | Percentage of cases with mechanical lung ventilation (% of patients) | 28 Days | |
Secondary | Mortality | Incidence of fatal cases (% of patients) | 28 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Active, not recruiting |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|